Predictive Vulnerability Intelligence.

Product

  • Product
  • Pricing
  • Documentation

Company

  • About
  • Partnerships
  • Blog
  • Support

Legal

  • Terms
  • Privacy
  • Data Licensing

© 2026 FAUCET Technologies LLC. All rights reserved.

CVE-2020-10553

16
FAUCET Score

CVE-2020-10553 affects Psyprax before version 3.2.2, allowing local users to bypass the application's lockscreen. By removing a specific hash entry from the PPScreen.ini file, the lockscreen is disabled, leaving the application unlocked. This vulnerability has a CVSS score of 5.5 (Medium), indicating a low attack complexity and requiring local user access, with a high impact on integrity but no impact on confidentiality or availability. There is no evidence of active exploitation, public exploit code, or significant community discussion surrounding this CVE.

Impacted Technologies

VendorProductVersion(s)CPE
< 3.2.2CPE matchmatch criteria
cpe:2.3:a:psyprax:psyprax:*:*:*:*:*:*:*:*

CVSS Data

CVSS version used by this source: 3.1

5.5MEDIUM

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:N

Attack Vector
LOCAL
Attack Complexity
LOW
Privileges Required
LOW
User Interaction
NONE
Scope
UNCHANGED
Confidentiality Impact
NONE
Integrity Impact
HIGH
Availability Impact
NONE
Exploitability Score
1.8
Impact Score
3.6
CvssVersion
3.1

Exploit Intelligence

EPSS Score
0.25%
Probability of exploitation in next 30 days
EPSS Percentile
15.9%
Percentile rank of EPSS score among Peer Group
As of 2026-07-27
Model: v2026.06.15
This CVE's current EPSS score of 0.0025 is in the 68th percentile among its peer group of 15,940 CVEs.

Social Chatter

No social media mentions found for this CVE.

The average CVE in this peer group has 0.0 Twitter, 0.0 Reddit, 0.0 Bluesky, 0.0 Mastodon, and 0.1 GitHub mentions.

Media Mentions

No media coverage found for this CVE.

The average CVE in this peer group has 0.1 InfoSec Media, 0.0 Vendor Blog, and 0.0 Security Researcher mentions.

Remediation

Remediation records are not available for this CVE.

References

x41-dsec.de / lab/advisories/x41-2020-002-psyprax
Third Party Advisory